Abstract： Objective： To observe the clinical effect of Huoxue Liangxue Jiedu prescription for chronic primary immune thrombocytopenic purpura. Methods：A total of 80 cases of patients with chronic primary immune thrombocytopenic purpura were selected and divided into the control group and the observation group according to the random number table method， 40 cases in each group. The control group was treated with prednisolone acetate tablets， and the observation group was additionally treated with Huoxue Liangxue Jiedu prescription based on the treatment of the control group， with 12 weeks being one course. Before and after treatment， the changes in blood platelet counts(BPC) and levels of platelet- related antibody including PAIgA， PAIgG and PAIgM in the two groups were compared. The clinical effect in the two groups was observed. Results： The total effective rate was 87.5% in the observation group and 65.0% in the control group， the difference being significant(P＜0.05). The total effective rate of TCM syndrome in the observation group was 92.5% and 70.0% in the control group，the difference being significant(P＜0.05). At 4，8 and 12 weeks of treatment，BPC in the two groups was increased when compared with the previous time point(P＜0.05)，and BPC count in the observation group was higher than that in the control group(P＜0.05). After treatment， the levels of PAIgA， PAIgG and PAIgM in the two groups were decreased when compared with those before treatment(P＜0.05)，and the above indexes in the observation group were lower than those in the control group(P＜0.05). Conclusion： The application of Huoxue Liangxue Jiedu prescription has significant effect in treating chronic primary immune thrombocytopenic purpura，which can significantly increase the platelet counts，reduce the levels of platelet- associated antibody and effectively relieve the clinical symptoms of patients.